ALK+ International awards its first grant of just under £50k to
The Institute of Cancer Research, London

News release


ALK+ International awards its first grant of just under £50k to The Institute of Cancer Research, London



LONDON, 10 November 2023 – ALK+ International is pleased to announce a gift of just under £50,000 to The Institute of Cancer Research, London, to build a tissue bank of ALK-positive and other oncogene-driven lung cancers, like EGFR. This tissue bank will support Dr Paul Huang at The Institute of Cancer Research (ICR), working in collaboration with Professor Sanjay Popat from The Royal Marsden NHS Foundation Trust, to study treatment resistance in ALK- and EGFR-positive oncogene-addicted lung cancers.

Over the next two to three years, Dr Huang will collect and prepare lung tumour samples from Professor Popat’s clinic for a molecular-based study of ALK+ patients. This funding will provide a structured framework within which both tissue and blood specimens can be collected from patients for analyses, allowing us to identify new tests as well as characterise how the tumours become resistant to targeted therapies. The ICR then hope to carry out experiments that underpin and drive the knowledge needed for Dr Huang and Professor Popat to reach their ultimate goal: to deliver an individualised approach to treatment and improve the long-term outcomes in ALK+ lung cancer patients, and beyond, who currently have a poor prognosis.

“ALK+ cancers are cancers of unmet clinical need and it’s often only possible for us to research cancers like this because of the incredible fundraising efforts of patient- and family-driven charities. We’re so grateful to have the support of ALK+ International to help us start this project into cancers caused by ALK+ mutations. Their support will help us put the infrastructure in place to do research towards developing better and kinder treatment strategies for people with ALK+ cancers,” says Dr Paul Huang, Molecular and Systems Oncology Group Leader at The Institute of Cancer Research, London.

ALK+ International co-founders and Trustees Joanna Jonathan, Jamie Gibbard and Cat Gibbard, are thrilled to hit this important milestone in the charity’s formation, adding: “Supporting life-changing research is the reason ALK+ International exists.  The ICR is one of the world’s leading cancer research institutions and we’re thrilled to support the work of Professor Popat and Dr Huang. This grant demonstrates that together we can make a difference. We are particularly grateful to everyone who donated and supported our ethos over the past 18 months.”


For more information, please contact: 

ALK+ International Press Office

advocacy@alkinternational.org



Notes to editors:

Facts about ALK-positive lung cancer


About ALK+ International

ALK+ International has a single mission: to increase the life expectancy of ALK+ cancer patients. We do this by fundraising for medical research, providing grants, advocating for patient interests, and collaborating with the wider medical, research, regulatory and patient groups. Learn more about us on: www.alkinternational.org. Follow us on Twitter, Instagram, Facebook LinkedIn, and YouTube





Support ALK+ International and join the conversation online.